Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decode Quanterix’s R&D spend, grant revenue and Simoa roll-out plans inside a 200-page disclosure can slow any analyst. That’s why our platform keeps Quanterix SEC filings explained simply. Stock Titan’s AI pinpoints the assays driving growth and flags accounting nuances the moment each document hits EDGAR.
Need the numbers fast? Our dashboard links every Quanterix quarterly earnings report 10-Q filing to AI commentary on instrument placements and consumable margins, while a single click delivers a Quanterix annual report 10-K simplified summary that highlights R&D burn and royalty obligations. Form 8-K alerts—think FDA assay clearances—arrive under the heading Quanterix 8-K material events explained. Executive pay questions? Open the latest Quanterix proxy statement executive compensation note and see side-by-side trend charts.
Real-time compliance matters too. Track every Quanterix insider trading Form 4 transactions notice or set instant e-mail triggers for Quanterix Form 4 insider transactions real-time. Use our heat-map to spot cluster buying, then overlay it with Quanterix earnings report filing analysis for context. Whether you’re understanding Quanterix SEC documents with AI before a funding round or reviewing Quanterix executive stock transactions Form 4 ahead of board meetings, the platform supplies complete coverage—10-K, 10-Q, 8-K, Form 4, S-1 and more—updated the instant Quanterix uploads to EDGAR.
Quanterix Corporation adjourned its shareholder meeting and scheduled an adjourned session for shareholders who pre-register by 10:00am ET on September 28, 2025 at the provided registration URL. The company reported that at the original meeting time shareholders who voted were overwhelmingly in favor of two proposals to eliminate supermajority vote requirements, with 99% of votes cast supporting those two proposals. However, the shares that voted in favor represented 74.8% of the company’s common stock outstanding. The filing is signed by Vandana Sriram, Chief Financial Officer, and lists contact and filing references.
Sriram Vandana, Chief Financial Officer of Quanterix Corporation (QTRX), reported a sale of common stock on 09/15/2025. The filing shows 229 shares disposed at a price of $4.97 per share, marked with code F and explained as shares withheld by the company to cover tax obligations arising from the vesting of 777 restricted stock units (RSUs). After the transaction, the reporting person beneficially owned 86,971 shares, which the filing notes includes 71,670 RSUs. The form is signed by an attorney-in-fact on behalf of the reporting person and reflects a routine tax-withholding disposition rather than an open-market sale for cash.
Toloue Masoud, who serves as President & CEO and a director of Quanterix Corporation (QTRX), reported a sale of 1,242 shares of common stock at $4.97 per share. The filing states these shares were disposed (code F) and that 3,722 restricted stock units vested, with shares withheld solely to cover tax obligations related to that vesting. After the reported transaction Masoud is shown as beneficially owning 513,192 shares in total, which include 224,330 restricted stock units.
Quanterix Corp (QTRX) insider purchase by CFO: The filing shows Sriram Vandana, Chief Financial Officer, acquired 4,150 shares of Quanterix common stock on 09/12/2025 at $4.79 per share. After the transaction Vandana beneficially owned 87,200 shares in total, which the filing notes includes 72,447 restricted stock units. The Form 4 was submitted with a signature executed by an attorney-in-fact on 09/15/2025. The document records a single non-derivative purchase and lists no derivative transactions or additional amendments.
Form 4 for Quanterix Corp (QTRX) shows Toloue Masoud, President & CEO and a director, reported transactions dated 08/31/2025. The filing records a disposition of 254 shares of common stock at $4.55 per share. The disposition reflects shares withheld by the company to cover tax obligations upon the vesting of 761 restricted stock units (RSUs). After the reported transaction, Masoud beneficially owns 514,434 shares, which include 228,052 RSUs. The form was signed by an attorney-in-fact on 09/03/2025.
Quanterix Corporation (QTRX) will hold a virtual 2025 Annual Meeting at 9:00 a.m. ET on September 23, 2025, with a record date of July 31, 2025 and 46,465,915 shares outstanding. The Proxy Statement asks stockholders to vote on six proposals: election of three directors (Myla Lai-Goldman, M.D., Masoud Toloue, Ph.D., and David Walt, Ph.D.), an advisory vote on executive compensation, ratification of KPMG LLP as independent auditors for 2025, and three Charter amendments to declassify the Board and remove supermajority vote requirements for certain Charter and Bylaw amendments. The filing discloses the closing of the Akoya Biosciences acquisition on July 8, 2025 and related board changes with appointments of former Akoya directors. The Company entered a Cooperation Agreement with Kent Lake Partners on August 4, 2025, including commitments to appoint a new independent director by December 1, 2025 and to seek Board declassification. Voting procedures, quorum, and broker voting limitations are described for each proposal.
Sriram Vandana, Chief Financial Officer and reporting person for Quanterix Corporation (QTRX), reported a change in beneficial ownership on 08/15/2025. The filing shows a disposition of 229 shares of Quanterix common stock at a price of $4.57. The filing explains those shares were withheld by Quanterix solely to cover tax obligations upon the vesting of 777 restricted stock units (RSUs). After the reported transaction, Vandana beneficially owns 83,050 shares, which the filing notes includes 72,447 restricted stock units. The form is signed by an attorney-in-fact on behalf of the reporting person on 08/19/2025.
Toloue Masoud, President & CEO and director of Quanterix Corporation (QTRX), reported a transaction dated 08/15/2025 showing a disposition of 1,242 shares of common stock at a price of $4.57 per share under transaction code F. The filing explains those shares were withheld by the company to cover tax obligations related to the vesting of 3,722 restricted stock units (RSUs). After the reported transaction, the reporting person beneficially owns 514,688 shares, which the filing notes includes 228,813 restricted stock units. The form was signed by an attorney-in-fact on 08/19/2025.